Kinase Inhibitor
WHO Essential Medicine EML section: Targeted therapies
This is information only, not a prescription. Talk to a doctor or pharmacist before taking any medicine. For an overdose or poisoning, call 102.
Nepal brand names not included: no licence-safe source.
is a kinase inhibitor indicated for the treatment of: Adult patients with chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL). Adult patients with chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) with 17p deletion. Adult patients with Waldenström’s macroglobulinemia (WM).
Ibrutinib is a small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). Ibrutinib forms a covalent bond with a cysteine residue in the BTK active site, leading to inhibition of BTK enzymatic activity. BTK is a signaling molecule of the B-cell antigen receptor (BCR) and cytokine receptor pathways.
The following clinically significant adverse reactions are described elsewhere in the labeling: Hemorrhage Infections Cardiac Arrhythmias, Cardiac Failure, and Sudden Death Hypertension Cytopenias Second Primary Malignancies Hepatotoxicity, including DILI Tumor Lysis Syndrome The most common (≥30%) adverse reactions in patients with B-cell...
None None
Pregnancy (label summary): Risk Summary IMBRUVICA can cause fetal harm based on findings from animal studies. There are no available data on IMBRUVICA use in pregnant women to inform a drug-associated risk of major birth defects and miscarriage. Advise pregnant women of the potential risk to a fetus.
For a suspected overdose or poisoning, call 102 now and go to the nearest emergency hospital.
Call 102What is Ibrutinib used for?
is a kinase inhibitor indicated for the treatment of: Adult patients with chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL). Adult patients with chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) with 17p deletion. Adult patients with Waldenström’s macroglobulinemia (WM).
How does Ibrutinib work?
Ibrutinib is a small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). Ibrutinib forms a covalent bond with a cysteine residue in the BTK active site, leading to inhibition of BTK enzymatic activity. BTK is a signaling molecule of the B-cell antigen receptor (BCR) and cytokine receptor pathways.
What are the side effects of Ibrutinib?
The following clinically significant adverse reactions are described elsewhere in the labeling: Hemorrhage Infections Cardiac Arrhythmias, Cardiac Failure, and Sudden Death Hypertension Cytopenias Second Primary Malignancies Hepatotoxicity, including DILI Tumor Lysis Syndrome The most common (≥30%) adverse reactions...
Who should not take Ibrutinib?
None None
Can I take Ibrutinib in pregnancy or while breastfeeding?
Pregnancy (label summary): Risk Summary IMBRUVICA can cause fetal harm based on findings from animal studies. There are no available data on IMBRUVICA use in pregnant women to inform a drug-associated risk of major birth defects and miscarriage. Advise pregnant women of the potential risk to a fetus.
What is the dose of Ibrutinib?
Not provided here. Ask a doctor or pharmacist.
What is Ibrutinib?
Ibrutinib is used for: is a kinase inhibitor indicated for the treatment of: Adult patients with chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL). It belongs to the class: Kinase Inhibitor. Common side effects include: The following clinically significant adverse reactions are described elsewhere …
Sources: FDA SPL label (openFDA/DailyMed); RxNorm (NLM) · Reference · Reference · Reference
US FDA DailyMed; NLM RxNorm